
	Three Months Ended September 30,
(in millions, except shares and per share amounts)	2026		2025
Basic net income per share attributable to common stockholders
Numerator:
Net income	$	2.2	$	38.7
Denominator:
Weighted average number of shares of common stock outstanding	291,557,934		316,966,947
Basic net income per share attributable to common stockholders	$	0.01	$	0.12

Diluted net income per share attributable to common stockholders
Numerator:
Net income	$	2.2	$	38.7
Denominator:
Number of shares used in basic computation	291,557,934		316,966,947
Add: weighted-average effect of dilutive securities exchangeable for common stock:



Liability-classified awards	1,348,862		—


Weighted average shares of common stock outstanding used to calculate diluted net income per share	292,906,796		316,966,947
Diluted net income per share attributable to common stockholders	$	0.01	$	0.12


	Nine Months Ended September 30,
(in millions, except shares and per share amounts)	2026		2025
Basic net income (loss) per share attributable to common stockholders
Numerator:
Net income (loss)	$	(612.2)	$	89.5
Denominator:
Weighted average number of shares of common stock outstanding	296,170,958		328,317,197
Basic net income (loss) per share attributable to common stockholders	$	(2.07)	$	0.27

Diluted net income (loss) per share attributable to common stockholders
Numerator:
Net income (loss)	$	(612.2)	$	89.5
Denominator:







Weighted average shares of common stock outstanding used to calculate diluted net income (loss) per share	296,170,958		328,317,197
Diluted net income (loss) per share attributable to common stockholders	$	(2.07)	$	0.27

In periods of loss, the number of shares used to calculate diluted net loss per share is the same as basic net loss per share. Potentially dilutive securities excluded due to their anti-dilutive effect were as follows:


	Three Months Ended September 30,		Nine Months Ended September 30,
	2026	2025	2026	2025

Restricted stock units	27,069,483	16,409,811	21,190,922	15,776,487
ESPP Shares	1,294,100	—	1,294,100	—
CEO Premium-Priced Performance Option	9,678,000	—	9,678,000	—
Liability-classified awards	—	—	1,348,862	—
Exercise of common stock options	163,660	186,026	179,660	225,899
Total anti-dilutive securities	38,205,243	16,595,837	33,691,544	16,002,386

Unless otherwise described in this Form 10-Q, for a description of the terms and conditions of these securities, refer to Note 13 – Equity-Based Compensation in our 2025 Form 10-K.